Treatment with JAK2 inhibitors and IL-6 neutralizing antibodies significantly inhibits the proliferation rate of HCC cells.[59] IL-6 binds to membrane receptors and induces activates the downstream JAK2/STAT3 pathway. The gene discussed is JAK2; the disease is hepatocellular carcinoma.